Many degenerative diseases involve apoptotic cell death -can they be treated with apoptosis inhibitors, while protecting the normal physiological function of the rescued cells? Reason for optimism comes from a recent study of mutant flies with an analogue of the human degenerative disease retinitis pigmentosa.
Although severely damaged cells often die by necrosis, the same initial injury in a less severe form usually induces programmed cell death. Thus, there is some sense to the idea that inhibiting programmed cell death may keep damaged cells alive. Indeed, inhibiting programmed cell death does seem to limit the amount of neuronal cell death after ischemic brain injury, and promotes functional recovery in animal models of stroke [3] [4] [5] . Such acute injury situations are a major focus of efforts to find therapeutic uses for inhibitors of programmed cell death. The case for inhibiting programmed cell death in degenerative diseases, however, in which the cellular damage is thought to be sustained, is much less clear. If a neuron, for example, is too severely damaged to maintain its physiological functions, rescuing it by blocking apoptosis may be useless -or worse, if the rescued cells behave abnormally.
The death programme has been evolutionarily conserved in animals, so it is possible to address this issue by blocking apoptosis in animal models that mimic human disease. Apoptosis has been studied in the fruitfly Drosophila melanogaster, for example, where many of the underlying mechanisms of programmed cell death are the same as in humans. Although the fruitfly may not seem like an obvious species in which to test treatments for neurodegenerative diseases -after all, one fly brain can fit inside most human ganglia -the advantages of Drosophila genetics make the species a powerful research tool. Furthermore, humans and flies are remarkably similar in terms of their basic cell biology, so flies are a good species in which to analyse the general biological correlates of more complex mechanisms in humans.
There are Drosophila mutants, for example, that have a form of age-related retinal neurodegeneration that is very similar to retinitis pigmentosa, a leading cause of blindness in humans. Retinitis pigmentosa is an inherited degenerative disease involving the loss of rod photoreceptor cells, and can be caused by any one of several mutations affecting proteins expressed in rod cells that are involved in signal transduction or protein transport. Similar mutations in humans and fruitflies are known that produce analogous phenotypes. Mutations in the rhodopsin gene, which encodes the light-receptor protein in rods, are the most common, accounting for about 30% of human autosomal dominant retinitis pigmentosa. Equivalent mutations in the Drosophila rhodopsin gene also cause age-related retinal degeneration [6] , suggesting that, despite the differences in photoreceptor physiology, these mutations cause photoreceptor death by a common mechanism.
In rodent models of retinitis pigmentosa, the rod deaths are apoptotic [7] [8] [9] , suggesting that the final common mechanism of these cell deaths in mammals, and possibly flies, is programmed cell death. The fact that such deaths are apoptotic is important: the molecular basis for programmed cell death is rapidly becoming understood, and there are several ways to inhibit it. The most immediately promising method is by blocking the activity of a family of proteases that mediate programmed cell death, the caspases. These are aspartate-directed cysteine proteases that seem to be essential for programmed cell death in animals. Synthesized as inactive zymogens, they are activated by cleavage at specific aspartic acids. Once activated, they activate other caspases in a protease cascade, eventually leading to the cleavage of specific target proteins and programmed cell death.
Davidson and Steller [10] have provided elegant proof that blocking caspases, and thereby programmed cell death, can rescue physiological function in fruitflies with mutations causing retinal degeneration. One such mutation, ninaE RH27 , is a dominant rhodopsin mutation -a cysteine for tyrosine substitution at residue 200 -with a human equivalent that causes severe retinitis pigmentosa. Retinal degeneration in these flies begins after about three weeks of age. The other retinal degeneration mutant tested, rdgC 306 , is caused by a deletion of a serine/threonine phosphatase that dephosphorylates light-activated rhodopsin. In homozygous rdgC 306 mutant flies, retinal degeneration begins after two days of exposure to constant light (dark-reared flies do not show a retinal degeneration phenotype). Although there is no known exact human analogue of this mutation, a mutation near the phosphorylation site of human rhodopsin causes autosomal dominant retinitis pigmentosa. In both types of mutant fly, the photoreceptor death was clearly apoptotic.
Davidson and Steller [10] blocked these cell deaths by making use of a broad-spectrum caspase-inhibitory protein, baculovirus p35, which has been shown to inhibit apoptosis in insects, nematodes and mammalian cells [11] [12] [13] [14] (Figure 1 ). Flies that were engineered to express p35 protein specifically in the eyes were crossed with the retinal degeneration (rd) mutant flies, and the rd/p35 offspring of these crosses were then compared with corresponding wild-type and rd mutant flies for signs of photoreceptor degeneration, apoptosis and visual function. The rd/p35 flies, unlike their corresponding rd relatives, showed no signs of retinal degeneration, and apoptosis was completely blocked. Most importantly, the visual function in rd/p35 flies was retained throughout their life.
The most obvious implication is that blocking programmed cell death with caspase inhibitors may be a therapeutically useful strategy for slowing or preventing loss of neural function in neurodegenerative diseases. Although this interpretation seems to be relatively straightforward, it is important to consider some of the complexities of caspases in mammals. The first is their heterogeneity. There are at least 14 caspases in humans, and they can be grouped into three main functional classes [15] : the interleukin-1β converting enzyme (ICE)-like caspases, which are involved in processing proinflammatory cytokines; the 'upstream' signalling caspases that cleave and activate downstream caspases; and the 'downstream' effector caspases, such as CPP32 (caspase-3), involved in the execution phase of the death programme. There are also multiple caspases in Drosophila -two have been reported so far -although it is not clear whether they fall into all the same functional classes as in mammals.
This functional diversity complicates the interpretation of experiments with caspase inhibitors. Some caspases are at the head of a signalling pathway that leads to activation of downstream caspases and programmed cell death. FLICE (caspase-8), for example, is involved in directly mediating the activation of death-signalling receptors, such as CD95 (Fas/Apo-1) and tumour necrosis factor receptor-1 (TNF-R1). Inhibiting this caspase blocks most downstream signalling events that result in programmed cell death. By contrast, inhibiting ICE-like caspases blocks production of certain inflammatory cytokines, but generally does not block programmed cell death directly. Inhibition of caspase-dependent cytokines may have the indirect effect of inhibiting programmed cell death, however, because some of the cytokines stimulate stresssignalling pathways. For example, blocking cytokine production or function -by blocking the receptors -has been observed to inhibit programmed cell death in vitro and in vivo. In mice, inhibiting interleukin-1 (IL-1) production and ICE activity, either by expression of dominant-negative proteins or by injecting peptide caspase inhibitors, confers resistance to cerebral ischemia [4, 16, 17] . Caspase-activated cytokines may thus be The putative stress-activated cell-death pathway in photoreceptor cells. The combination of light and altered protein -such as mutant rhodopsin -triggers signals that lead to caspase activation and apoptosis. The caspase inhibitor p35 blocks this apoptosis; surprisingly, p35 also maintains normal cell physiology [10] . Survival factors can also inhibit retinal degeneration. Little is known about the apoptosis-inducing pathways, upstream of caspase activation, that are trigged by mutant or altered proteins. important in triggering programmed cell death in some circumstances, such as after a stroke.
Photoreceptor cell
The differences between cytokine-producing, upstream and downstream caspases may in fact be more blurred than this distinction implies -CPP32, for example, which behaves most clearly as a downstream caspase, has been found to process a cytokine [18] . This complexity will pose a challenge to understanding the role of caspases in chronic degenerative diseases, where the role of programmed cell death is not clear. In amyotrophic lateral sclerosis (ALS), for example, inhibiting ICE-like caspases in an animal model of the disease (by using a dominantnegative form of ICE) seems to slow the progression of motorneuron loss and paralysis that occurs after disease onset [19] . It is not known, however, whether this effect is a result of inhibiting cytokine production, blocking programmed cell death or both. One message from these findings is that therapies should target stress-signalling pathways that are upstream of the death programme. Caspase inhibitors can affect both pathways.
Another issue is whether blocking caspases can keep most cells alive even if apoptosis is prevented. This complication is suggested by some observations in cell culture in which peptide caspase inhibitors, although effective in blocking apoptosis induced by an activated oncogene or by changing culture conditions, did not rescue the cells from eventual death [20, 21] . One possibility is that some death-signalling events upstream of caspases, such as mitochondrial pore-opening, eventually kill the cell despite the caspase blockade. Alternatively, the peptide inhibitors might not be completely effective in some cells and conditions, perhaps because they are metabolised differently. Nevertheless, even if one assumes a perfectly effective caspase inhibitor, the problem remains of whether inhibiting caspases can be an effective treatment over many years, as would be required for an anti-degenerative drug in humans. In fruitflies, normal cell function needs to be maintained for mere weeks.
Despite all of these problems in extrapolating to humans, it remains a big surprise that the rd/p35 flies were able to see throughout their lives, and therefore that the photoreceptor cells were completely normal. Whatever the complexities of caspase biochemistry or cell pathology, it is encouraging that blocking caspases rescued retinal function at all, especially as the underlying cell damage caused by the rd mutation was unaffected. One possible explanation for these cells' ability to function is that they were not actually as severely damaged as one might assume. Although cells can respond to stressful stimuli by activating the death programme, the insult can be minor. DNA damaging treatments, for example, can activate the p53 protein -a DNA-damage detector that can induce apoptosis or cell-cycle arrest -with as little as one DNA double-strand break per cell [22] . Analogously, a relatively subtle mutation affecting an abundant protein might nevertheless trigger programmed cell death in a photoreceptor, possibly by activating a signalling pathway that responds to misfolded, mistargeted or aggregated proteins. Indeed, there is support for the idea that aberrant protein aggregation might be important in neurodegenerative disease [23] .
Complete functional rescue of every cell may not be needed, however, if some of the deaths are not cellautonomous [24] . In rd fruitflies, only six of the eight photoreceptor cells (R1-6) in every ommatidium express the mutant form of rhodopsin, and these cells die first. The other two photoreceptor cells (R7 and R8) express a different form of rhodopsin and are not directly affected, but they die shortly after the R1-6 cells, suggesting that they require signals from the R1-6 cells to survive. The equivalent human disease is remarkably similar: in retinitis pigmentosa, the rods are directly affected and die first, producing night blindness. This does not result in daylight blindness, however, as the colour-sensitive cone cells remain. Yet the cones, although not directly affected by the disease mutation, eventually die, leading to complete blindness. The simplest explanation is that the rods provide survival signals to the cones. Protecting the rods may thus at least have the indirect benefit of keeping the cones alive, thereby preventing total blindness, clearly much more debilitating than night blindness. The same argument applies to other neurodegenerative diseases, as it is generally a subpopulation of neurons that is initially affected; keeping damaged cells alive, even if they are not fully functional, may support the survival of neighbouring undamaged cells that depend on them for survival signals, thus maintaining the integrity of the overall tissue.
The main lesson from the Drosophila studies is that an apoptosis inhibitor can prevent a neurodegenerative disease. One may therefore be forgiven for being optimistic about the prospects for treatment of human neurodegeneration. Although effective treatments will take some time to develop, it is worth keeping in mind that most of the current research in apoptosis involves a relatively limited number of reagents directed against a few components of the death programme. As we understand the mechanisms of cell death more fully, and as more reagents that affect various cell death pathways become widely available, the full potential for this approach will become more apparent. Preventing blindness in fruitflies may not seem like a huge step, but it is the first. 
